This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Applying the Latest Evidence to Improve Care for Patients with HR+/HER2- Metastatic Breast Cancer

Applying the Latest Evidence to Improve Care for Patients with HR+/HER2- Metastatic Breast Cancer

Format

Slide Lecture Series

Time to Complete

1 hour

Released

December 13, 2018

Expires

December 13, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hours (0.90 pharmacotherapeutic contact hours)

Accredited Provider



Provided by The American Academy of CME, Inc.

Commercial Supporter

Supported by an educational grant from AstraZeneca Pharmaceuticals LP

Program Description

Scientific advances in biomarker testing and drug development are leading to new ways of managing patients with HR+/HER2- metastatic breast cancer. Recently, the FDA approved or expanded the approval of several new agents for the management of patients with metastatic breast cancer. The care of patients with metastatic breast cancer is becoming increasingly complex and there is a growing need to ensure that members of the cancer care team are working together to provide the best possible care that driven by the latest evidence. Continuing education can ensure that clinicians are employing effective models of team-based care coordination and implementing systems-based processes that are designed to improve the management of patients with HR+/HER2- metastatic breast cancer.

Intended Audience

Oncology physicians, advanced practice providers, nurses, and other members of the healthcare team involved in the care of patients with metastatic breast cancer

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Review the latest clinical evidence around the management of patients with HR+/HER2- metastatic breast cancer
  • Apply clinical practice guidelines to formulate treatment plans for patients with HR+/HER2- metastatic breast cancer
  • Describe key areas where team-based care coordination and systems-level processes can improve the management of patients with HR+/HER2- metastatic breast cancer

Conflicts of Interest Disclosure Policy

As the accredited provider, American Academy of CME, Inc (Academy) will retain responsibility for the educational and clinical content of this activity. The Academy will assure compliance with all applicable Essentials, Policies, Standards, and government regulations regarding the provision of continuing medical education. This includes, but is not limited to, FDA, OIG, PhRMA Code, ANCC, ACCME, and AMA. The Academy will assure all decisions regarding this activity were made free of the control of the commercial interest, including but not limited to selection of faculty and validation of clinical content. The Academy will obtain all relevant disclosures and document process implemented to resolving all conflicts of interest regarding any faculty and any persons who have the ability to affect content.

Faculty

VK Gadi, MD PhD
Associate Professor of Medicine, Division of Oncology, University of Washington
Associate Member Clinical Research Division, Fred Hutchinson Cancer Research Center
Medical Oncologist, Seattle Cancer Care Alliance

Dr. Gadi discloses the following: Seattle Genetics (Scientific Advisory Board, Consultant); SEngine Precision Medicine (Consultant, Shareholder, Intellectual Property/Patents); Genentech (Grant Recipient/Research Support); PNP Therapeutics (Intellectual Property/Patents); Verastem (Shareholder); Immunomedics (Shareholder); Rafael Holdings Inc (Shareholder); ImmunoGen (Shareholder)

Heidi Trott, MN, ARNP
Advanced Registered Nurse Practitioner (ARNP)
Breast Oncology and Women's Wellness Clinic
Seattle Cancer Care Alliance

Dr. Trott has no relevant financial relationships with any commercial interests.

Accredited Provider Disclosure

John JD Juchniewicz, MCIS, CHCP; Paul J. Minter MS; and Natalie Kirkwood, RN, BSN, JD, Lead Nurse Planner, American Academy of CME: No relevant financial relationships with any commercial interests.

Independent external reviewer: Marcus Flores, PharmD has no relevant financial relationships with any commercial interests.

Publishing Staff Disclosures

Joseph Kim, MD, MPH, MBA, Q Synthesis LLC: No relevant financial relationships with any commercial interests.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American Academy of CME, Inc. and Q Synthesis LLC. The American Academy of CME, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The American Academy of CME, Inc. designates this activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

The American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. American Academy of CME, Inc approved by the California Board of Registered Nursing, Provider Number CEP 16993.

Designation Statement

The American Academy of CME, Inc. designates this educational activity for 1.00 contact hours (0.90 pharmacotherapeutic contact hours). American Academy of CME, Inc approved by the California Board of Registered Nursing, Provider Number CEP 16993 for 1.00 contact hours.

Disclosure of Unlabeled Use

This activity will not review off-label or investigational information.

Disclaimer

According to the disclosure policy of the Academy, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any significant relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed. If a conflict is identified, it is the responsibility of the Academy to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the activity.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of Academy, Q Synthesis LLC, or American Nurses Credentialing Center’s Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Instructions

In order to receive credit, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue